Technical Data
KLKB1, CT (KLKB1, KLK3, Plasma kallikrein, Fletcher factor, Kininogenin, Plasma prekallikrein, Plasma kallikrein heavy chain, Plasma kallikrein light chain)
Plasma prekallikrein is a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. It is synthesized in the liver and secreted into the blood as a single polypeptide chain. Plasma prekallikrein is converted to plasma kallikrein by factor XIIa by the cleavage of an internal Arg-Ile bond. Plasma kallikrein therefore is composed of a heavy chain and a light chain held together by a disulphide bond. The heavy chain originates from the amino-terminal end of the zymogen and contains 4 tandem repeats of 90 or 91 amino acids. Each repeat harbors a novel structure called the apple domain. The heavy chain is required for the surface-dependent pro-coagulant activity of plasma kallikrein. The light chain contains the active site or catalytic domain of the enzyme and is homologous to the trypsin family of serine proteases. Plasma prekallikrein deficiency causes a prolonged activated partial thromboplastin time in patients.

Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilutions:
Western Blot: 1:1000
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
200ul-20CBlue IceHumanRabbit
As Reported
KLH-conjugated synthetic peptide mapping to a fragment of residues within amino acids 508-537 in the C-terminal region of human KLKB1, UniProt Accession #P03952.
Purified by Protein A affinity chromatography.
Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
Recognizes human KLKB1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. MacKenzie, J.A., et al. Appl Physiol Nutr Metab 35(4):518-525(2010). 2. Han, S., et al. Hum. Immunol. 71(7):727-730(2010). 3. Rajaraman, P., et al. Cancer Epidemiol. Biomarkers Prev. 19(5):1356-1361(2010). 4. Eeckhoudt, S.L., et al. Thromb. Haemost. 103(4):866-867(2010). 5. Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010)